**Standard Operating Procedure (SOP) for the meta-analysis**

**Jennifer Hwang**

**I. Clinical Trials.gov**

1. Open ClinicalTrials.gov and search for the following terms included up to June 2019.
   1. Allopurinol and urate
   2. Allopurinol
   3. Febuxostat and urate
   4. Febuxostat
   5. Gout and urate
   6. Gout
   7. Hyperuricemia and urate
   8. Hyperuricemia
   9. Topiroxostat
2. Under the Search Results Page, click each trial title to record the trial information. The definitions of each term are defined by Clinical Trials.gov.
   1. Query
      1. Search terms that were used to search for trials.
   2. NCT number
      1. The unique identification code given to each clinical study upon registration at ClinicalTrials.gov, The format is “NCT” followed by an 8-digit number.
   3. Trial Title
   4. Status
      1. The current recruitment status or the expanded access status
   5. Study result
      1. Status whether a trial yielded a study result or not
   6. Associated conditions
      1. The disease, disorder, syndrome, illness or injury that is being studied.
   7. Interventions
      1. The general design of the strategy for assigning interventions to participants in a clinical study.
   8. Outcome measures
      1. It describes the measurements planned in the study protocol that are used to determine the effects of intervention or treatment on participants.
   9. Study Phase
      1. The stage of a clinical trial studying a drug of biological product
   10. Enrollment
       1. The number of participants in a clinical study.
   11. Start Date
       1. The start date of the trial
   12. End Date
       1. The end date of the trial
   13. Last update
       1. Last update date of each trial’s information
   14. URL
       1. ClinicalTrials.gov site address belongs to each trial
3. Mark the duplicate trials on separate cell. Mark duplicate if the trials are included in the results from other search queries or search database such as Embase or Drugs journal.
4. Based on inclusion and exclusion criteria, mark trials that is selected for meta-analysis
   1. Inclusion criteria
      1. Trials with following indications: gout, hyperuricemia and tumor lysis syndrome
   2. Exclusion criteria
      1. Normal range of baseline serum uric acid
      2. Dosage other than once daily
      3. Absence of dose titration
      4. Absence of uric lowering data availability
      5. Absence of CKD diagnosis availability
      6. Existence of placebo or colchicine trial arms
5. Open a new Excel file to record the information regarding the trial. Name the file accordingly as “Urate Meta-Analysis Clinical Trials Tracker\_All Elligible Trials”.
   1. Source
      1. Data source from either ClinicalTrials.gov, Embase, Drugs journal
   2. ID
      1. Study’s arm identification number
   3. Reference number
      1. Clinical trial or journal article identification number
   4. Article authors
      1. Authors of article as listed in the article
   5. NCT number
      1. ClinicalTrials.gov identification number
   6. SUALower\_Exclusion\_Reason
      1. Reason for exclusion for SUA lowering analysis
   7. SUALower\_Inclusion\_Reason
      1. Either drug or group of trial arm which was included for SUA lowering analysis
   8. AD\_Exclusion\_Reason
      1. Reason for exclusion for achievement difference analysis
   9. AD\_Inclusion\_ctrl
      1. Either drug or group of trial arm which was included for AD analysis
   10. Status
       1. Status of clinical trial
   11. Study results
       1. Results of clinical trial
   12. Conditions
       1. Disease of being investigated
   13. Interventions
       1. The independent variable
   14. Primary outcome
       1. Goal of clinical trial
   15. Secondary outcome
       1. Secondary goal of clinical trial
   16. Phases
       1. Stage of pharmaceutical development
   17. Enrollment
       1. Total number of subjects in clinical trial
   18. Start date
       1. Clinical trial start date
   19. Completion date
       1. Clinical trial end date
   20. Last\_Update\_Posted
       1. Most recent update of clinical trial
   21. URL
       1. Website address to each study’s ClinicalTrials.gov webpage
   22. Sponsor
       1. Name of clinical trial’s sponsor
   23. NDA/ANDA/BLA
       1. Unique FDA-provided number for FDA-approved drugs
   24. Drug
       1. Drug provided to a specific arm of clinical trial
   25. Drug\_Class
       1. Subgroup of drug
   26. Control
       1. Identifies whether the control arm for the trial was an experimental arm
   27. Placebo\_ctrl
       1. Identifies whether the control arm for the trial was a placebo arm
   28. Filter
       1. Identifies whether average baseline SUA of trial arm is hyperuricemic, SUA > 6.8, or normouricemic
   29. Dose
       1. Dose prescribed to patients in a specific clinical trial arm
   30. Drug\_Delivery\_Route
       1. The method in which the drug is delivered to the patient
   31. Dose\_Frequency
       1. How many times drug is administered to patients
          1. Once - Drug is taken only on Day 1 of study
          2. Q8h - drug is administered every 8 hours
          3. Every 4 days - drug is administered every 4 days
          4. Daily - drug is administered 1 time per day
          5. Twice daily - drug is administered 2 times per day
          6. Weekly - drug is administered 1 time per week
          7. Biweekly - drug is administered 1 time per every 2 weeks
          8. Triweekly - drug is administered 1 time per every 3 weeks
          9. Monthly - drug is administered 1 time per every 4 weeks
          10. Single on day 1; as needed on days 2-5 - self-explanatory, unique to one clinical trial"
   32. Daily\_Dose\_mg
       1. Dose of drug provided to patients provided in milligrams
   33. Number\_Arm
       1. Number of patients in clinical trial arm
   34. Number\_Male
       1. Number of patients who identify as male in the clinical trial arm
   35. Number\_Female
       1. Number of patients who identify as female in the clinical trial arm
   36. Region
       1. Area where the trial was conducted
   37. Baseline\_GFR
       1. Initial Glomerular Filtration Rate (GFR) in mL/min
   38. Baseline\_GFR\_SD
       1. Standard Deviation of baseline GFR in mL/min
   39. Renal\_Impairment\_(Y/N)
       1. Indicator of Renal Impairment Status
   40. Renal\_Impairment\_#
       1. Indicator of Renal Impairment Status
   41. Renal\_Impairment\_Comments
       1. Trial's definition of renal impairment and % of subjects classified as renally impaired
   42. CKD
       1. Notes whether CKD patients were included
   43. No\_Data
       1. Notes whether CKD data was present
   44. Initial\_sUA\_mg/dL
       1. Notes whether CKD data was present
   45. SD(Initial\_sUA\_mg/dL)
       1. Standard Deviation of Initial serum Urate Level in mg/dL
   46. SE(Initial\_sUA\_mg/dL)
       1. Standard Deviation of Initial serum Urate Level in mg/dL
   47. LL\_95%\_CI((Initial\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Initial serum Urate Level in mg/dL
   48. UL\_95%\_CI((Initial\_sUA\_mg/dL)
       1. Upper Limit 95% Confidence Interval for Initial serum Urate Level in mg/dL
   49. Initial\_sUA\_SI
       1. Initial serum Urate level in μM/L
   50. SD(Initial\_sUA\_SI)
       1. Standard Deviation of Initial serum Urate level in μM/L
   51. SE(Initial\_sUA\_SI)
       1. Standard Error of Initial serum Urate level in μM/L
   52. LL\_95%\_CI(Initial\_sUA\_SI)
       1. Lower Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   53. UL\_95%\_CI(Initial\_sUA\_SI)
       1. Upper Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   54. Final\_sUA\_mg/dL
       1. Upper Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   55. SD(Final\_sUA\_mg/dL)
       1. Standard Deviation of Final serum Urate level in μM/L
   56. SE(Final\_sUA\_mg/dL)
       1. Standard Error of Final serum Urate level in μM/L
   57. LL\_95%\_CI(Final\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Final serum Urate level in μM/L
   58. UL\_95%\_CI(Final\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Final serum Urate level in μM/L
   59. Final\_sUA\_SI
       1. Final serum Urate level in μM/L
   60. SD(Final\_sUA\_SI)
       1. Final serum Urate level in μM/L
   61. SE(Final\_sUA\_SI)
       1. Standard Error of Final serum Urate level in μM/L
   62. LL\_95%\_CI(Final\_sUA\_SI)
       1. Standard Error of Final serum Urate level in μM/L
   63. UL\_95%\_CI(Final\_sUA\_SI)
       1. Upper Limit 95% Confidence Interval for Final serum Urate level in μM/L
   64. Numeric Change in Uric Acid (mg/dL)
       1. Baseline SUA less final SUA
   65. Change
       1. Percentage of Urate Lowering converted to decimal format
   66. change.sd
       1. Standard Deviation of Percentage of Urate Lowering converted to decimal format
   67. change.se
       1. Standard Error of Percentage of Urate Lowering converted to decimal format
   68. Per
       1. Standard Error of Percentage of Urate Lowering converted to decimal format
   69. per.sd
       1. Standard Deviation of Percentage of Urate Lowering
   70. per.se
       1. Standard Deviation of Percentage of Urate Lowering
   71. LL\_95%\_CI(%\_UA\_Lowering)
       1. Lower Limit 95% Confidence Interval for Percentage of Urate Lowering
   72. UL\_95%\_CI(%\_UA\_Lowering)
       1. Lower Limit 95% Confidence Interval for Percentage of Urate Lowering
   73. Achieved\_Outcome\_%
       1. Percentage of patients achieving a specific outcome
   74. Number\_Achieved\_Outcome
       1. Number of patients achieving specific outcome
   75. Number\_NOT\_Achieved\_Outcome
       1. Number of patients failing to achieve a specific outcome
   76. SD(Achieved\_Outcome\_%)
       1. Standard Deviation of percentage of patients achieving a specific outcome
   77. SE(Achieved\_Outcome\_%)
       1. Standard Error of percentage of patients achieving a specific outcome
   78. LL\_95%\_CI(Achieved\_Outcome\_%)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   79. UL\_95%\_CI(Achieved\_Outcome\_%)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   80. Achieved\_Outcome\_P(x)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   81. LL\_95%\_CI(Achieved\_Outcome\_P(x))
       1. Lower Limit 95% Confidence Interval of the probability of achieving a specific outcome
   82. UL\_95%\_CI(Achieved\_Outcome\_P(x))
       1. Upper Limit 95% Confidence Interval of the probability of achieving a specific outcome
   83. ctrl.n
       1. Number of patients in the control trial arm for Achievement Difference analysis
   84. ctrl.ac
       1. Number of patients in the control trial arm for Achievement Difference analysis
   85. ctrl.nac
       1. Number of patients in control arm failing to achieve a specific outcome
   86. RR
       1. Relative Risk relating to the Control Arm
   87. SE(RR)
       1. Relative Risk relating to the Control Arm
   88. Days\_on\_Tx
       1. Number of days patients were on treatment
   89. Comments
       1. Number of days patients were on treatment
   90. Comments\_2
       1. Number of days patients were on treatment
   91. Uric Acid SI Unit Conversion Factor
       1. Number of days patients were on treatment

**II. Embase**

1. Open Embase.com and search for the following terms limiting up to June 2019.
   1. Allopurinol and urate
   2. Allopurinol
   3. Febuxostat and urate
   4. Febuxostat
   5. Gout and urate
   6. Gout
   7. Hyperuricemia and urate
   8. Hyperuricemia
   9. Topiroxostat
2. Use the orange bullets to edit Mapping options.
3. Use the limiters to the right of Mapping to narrow your search.
   1. These limiters include:
4. Click 'Search' to proceed
5. Mark the duplicate trials on separate cell. Mark duplicate if the trials are included in the results from other search queries or search database such as ClinicalTrials.gov or Drugs journal.
6. Based on inclusion and exclusion criteria, mark trials that is selected for meta-analysis
   1. Inclusion criteria
      1. Trials with following indications: gout, hyperuricemia and tumor lysis syndrome
   2. Exclusion criteria
      1. Normal range of baseline serum uric acid
      2. Dosage other than once daily
      3. Absence of dose titration
      4. Absence of uric lowering data availability
      5. Absence of CKD diagnosis availability
      6. Existence of placebo or colchicine trial arms
7. Record the information in the Excel file name under “Urate Meta-Analysis Clinical Trials Tracker\_All Elligible Trials”.
   1. Source
      1. Data source from either ClinicalTrials.gov, Embase, Drugs journal
   2. ID
      1. Study’s arm identification number
   3. Reference number
      1. Clinical trial or journal article identification number
   4. Article authors
      1. Authors of article as listed in the article
   5. NCT number
      1. ClinicalTrials.gov identification number
   6. SUALower\_Exclusion\_Reason
      1. Reason for exclusion for SUA lowering analysis
   7. SUALower\_Inclusion\_Reason
      1. Either drug or group of trial arm which was included for SUA lowering analysis
   8. AD\_Exclusion\_Reason
      1. Reason for exclusion for achievement difference analysis
   9. AD\_Inclusion\_ctrl
      1. Either drug or group of trial arm which was included for AD analysis
   10. Status
       1. Status of clinical trial
   11. Study results
       1. Results of clinical trial
   12. Conditions
       1. Disease of being investigated
   13. Interventions
       1. The independent variable
   14. Primary outcome
       1. Goal of clinical trial
   15. Secondary outcome
       1. Secondary goal of clinical trial
   16. Phases
       1. Stage of pharmaceutical development
   17. Enrollment
       1. Total number of subjects in clinical trial
   18. Start date
       1. Clinical trial start date
   19. Completion date
       1. Clinical trial end date
   20. Last\_Update\_Posted
       1. Most recent update of clinical trial
   21. URL
       1. Website address to each study’s ClinicalTrials.gov webpage
   22. Sponsor
       1. Name of clinical trial’s sponsor
   23. NDA/ANDA/BLA
       1. Unique FDA-provided number for FDA-approved drugs
   24. Drug
       1. Drug provided to a specific arm of clinical trial
   25. Drug\_Class
       1. Subgroup of drug
   26. Control
       1. Identifies whether the control arm for the trial was an experimental arm
   27. Placebo\_ctrl
       1. Identifies whether the control arm for the trial was a placebo arm
   28. Filter
       1. Identifies whether average baseline SUA of trial arm is hyperuricemic, SUA > 6.8, or normouricemic
   29. Dose
       1. Dose prescribed to patients in a specific clinical trial arm
   30. Drug\_Delivery\_Route
       1. The method in which the drug is delivered to the patient
   31. Dose\_Frequency
       1. How many times drug is administered to patients
          1. Once - Drug is taken only on Day 1 of study
          2. Q8h - drug is administered every 8 hours
          3. Every 4 days - drug is administered every 4 days
          4. Daily - drug is administered 1 time per day
          5. Twice daily - drug is administered 2 times per day
          6. Weekly - drug is administered 1 time per week
          7. Biweekly - drug is administered 1 time per every 2 weeks
          8. Triweekly - drug is administered 1 time per every 3 weeks
          9. Monthly - drug is administered 1 time per every 4 weeks
          10. Single on day 1; as needed on days 2-5 - self-explanatory, unique to one clinical trial"
   32. Daily\_Dose\_mg
       1. Dose of drug provided to patients provided in milligrams
   33. Number\_Arm
       1. Number of patients in clinical trial arm
   34. Number\_Male
       1. Number of patients who identify as male in the clinical trial arm
   35. Number\_Female
       1. Number of patients who identify as female in the clinical trial arm
   36. Region
       1. Area where the trial was conducted
   37. Baseline\_GFR
       1. Initial Glomerular Filtration Rate (GFR) in mL/min
   38. Baseline\_GFR\_SD
       1. Standard Deviation of baseline GFR in mL/min
   39. Renal\_Impairment\_(Y/N)
       1. Indicator of Renal Impairment Status
   40. Renal\_Impairment\_#
       1. Indicator of Renal Impairment Status
   41. Renal\_Impairment\_Comments
       1. Trial's definition of renal impairment and % of subjects classified as renally impaired
   42. CKD
       1. Notes whether CKD patients were included
   43. No\_Data
       1. Notes whether CKD data was present
   44. Initial\_sUA\_mg/dL
       1. Notes whether CKD data was present
   45. SD(Initial\_sUA\_mg/dL)
       1. Standard Deviation of Initial serum Urate Level in mg/dL
   46. SE(Initial\_sUA\_mg/dL)
       1. Standard Deviation of Initial serum Urate Level in mg/dL
   47. LL\_95%\_CI((Initial\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Initial serum Urate Level in mg/dL
   48. UL\_95%\_CI((Initial\_sUA\_mg/dL)
       1. Upper Limit 95% Confidence Interval for Initial serum Urate Level in mg/dL
   49. Initial\_sUA\_SI
       1. Initial serum Urate level in μM/L
   50. SD(Initial\_sUA\_SI)
       1. Standard Deviation of Initial serum Urate level in μM/L
   51. SE(Initial\_sUA\_SI)
       1. Standard Error of Initial serum Urate level in μM/L
   52. LL\_95%\_CI(Initial\_sUA\_SI)
       1. Lower Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   53. UL\_95%\_CI(Initial\_sUA\_SI)
       1. Upper Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   54. Final\_sUA\_mg/dL
       1. Upper Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   55. SD(Final\_sUA\_mg/dL)
       1. Standard Deviation of Final serum Urate level in μM/L
   56. SE(Final\_sUA\_mg/dL)
       1. Standard Error of Final serum Urate level in μM/L
   57. LL\_95%\_CI(Final\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Final serum Urate level in μM/L
   58. UL\_95%\_CI(Final\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Final serum Urate level in μM/L
   59. Final\_sUA\_SI
       1. Final serum Urate level in μM/L
   60. SD(Final\_sUA\_SI)
       1. Final serum Urate level in μM/L
   61. SE(Final\_sUA\_SI)
       1. Standard Error of Final serum Urate level in μM/L
   62. LL\_95%\_CI(Final\_sUA\_SI)
       1. Standard Error of Final serum Urate level in μM/L
   63. UL\_95%\_CI(Final\_sUA\_SI)
       1. Upper Limit 95% Confidence Interval for Final serum Urate level in μM/L
   64. Numeric Change in Uric Acid (mg/dL)
       1. Baseline SUA less final SUA
   65. Change
       1. Percentage of Urate Lowering converted to decimal format
   66. change.sd
       1. Standard Deviation of Percentage of Urate Lowering converted to decimal format
   67. change.se
       1. Standard Error of Percentage of Urate Lowering converted to decimal format
   68. Per
       1. Standard Error of Percentage of Urate Lowering converted to decimal format
   69. per.sd
       1. Standard Deviation of Percentage of Urate Lowering
   70. per.se
       1. Standard Deviation of Percentage of Urate Lowering
   71. LL\_95%\_CI(%\_UA\_Lowering)
       1. Lower Limit 95% Confidence Interval for Percentage of Urate Lowering
   72. UL\_95%\_CI(%\_UA\_Lowering)
       1. Lower Limit 95% Confidence Interval for Percentage of Urate Lowering
   73. Achieved\_Outcome\_%
       1. Percentage of patients achieving a specific outcome
   74. Number\_Achieved\_Outcome
       1. Number of patients achieving specific outcome
   75. Number\_NOT\_Achieved\_Outcome
       1. Number of patients failing to achieve a specific outcome
   76. SD(Achieved\_Outcome\_%)
       1. Standard Deviation of percentage of patients achieving a specific outcome
   77. SE(Achieved\_Outcome\_%)
       1. Standard Error of percentage of patients achieving a specific outcome
   78. LL\_95%\_CI(Achieved\_Outcome\_%)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   79. UL\_95%\_CI(Achieved\_Outcome\_%)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   80. Achieved\_Outcome\_P(x)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   81. LL\_95%\_CI(Achieved\_Outcome\_P(x))
       1. Lower Limit 95% Confidence Interval of the probability of achieving a specific outcome
   82. UL\_95%\_CI(Achieved\_Outcome\_P(x))
       1. Upper Limit 95% Confidence Interval of the probability of achieving a specific outcome
   83. ctrl.n
       1. Number of patients in the control trial arm for Achievement Difference analysis
   84. ctrl.ac
       1. Number of patients in the control trial arm for Achievement Difference analysis
   85. ctrl.nac
       1. Number of patients in control arm failing to achieve a specific outcome
   86. RR
       1. Relative Risk relating to the Control Arm
   87. SE(RR)
       1. Relative Risk relating to the Control Arm
   88. Days\_on\_Tx
       1. Number of days patients were on treatment
   89. Comments
       1. Number of days patients were on treatment
   90. Comments\_2
       1. Number of days patients were on treatment
   91. Uric Acid SI Unit Conversion Factor
       1. Number of days patients were on treatment

**III. Drugs journal**

1. Open Springer.com/journal/40265
2. Click search to search within the Drugs journal
3. Search for the following terms limiting up to June 2019.
   1. Allopurinol
   2. Benzbromarone
   3. Febuxostat
   4. Lesinurad
   5. Pegloticase
   6. Rasburicase
4. Mark the duplicate trials on separate cell. Mark duplicate if the trials are included in the results from other search queries or search database such as ClinicalTrials.gov or Drugs journal.
5. Based on inclusion and exclusion criteria, mark trials that is selected for meta-analysis
   1. Inclusion criteria
      1. Trials with following indications: gout, hyperuricemia and tumor lysis syndrome
   2. Exclusion criteria
      1. Normal range of baseline serum uric acid
      2. Dosage other than once daily
      3. Absence of dose titration
      4. Absence of uric lowering data availability
      5. Absence of CKD diagnosis availability
      6. Existence of placebo or colchicine trial arms
6. Record the information in the Excel file name under “Urate Meta-Analysis Clinical Trials Tracker\_All Elligible Trials”.
   1. Source
      1. Data source from either ClinicalTrials.gov, Embase, Drugs journal
   2. ID
      1. Study’s arm identification number
   3. Reference number
      1. Clinical trial or journal article identification number
   4. Article authors
      1. Authors of article as listed in the article
   5. NCT number
      1. ClinicalTrials.gov identification number
   6. SUALower\_Exclusion\_Reason
      1. Reason for exclusion for SUA lowering analysis
   7. SUALower\_Inclusion\_Reason
      1. Either drug or group of trial arm which was included for SUA lowering analysis
   8. AD\_Exclusion\_Reason
      1. Reason for exclusion for achievement difference analysis
   9. AD\_Inclusion\_ctrl
      1. Either drug or group of trial arm which was included for AD analysis
   10. Status
       1. Status of clinical trial
   11. Study results
       1. Results of clinical trial
   12. Conditions
       1. Disease of being investigated
   13. Interventions
       1. The independent variable
   14. Primary outcome
       1. Goal of clinical trial
   15. Secondary outcome
       1. Secondary goal of clinical trial
   16. Phases
       1. Stage of pharmaceutical development
   17. Enrollment
       1. Total number of subjects in clinical trial
   18. Start date
       1. Clinical trial start date
   19. Completion date
       1. Clinical trial end date
   20. Last\_Update\_Posted
       1. Most recent update of clinical trial
   21. URL
       1. Website address to each study’s ClinicalTrials.gov webpage
   22. Sponsor
       1. Name of clinical trial’s sponsor
   23. NDA/ANDA/BLA
       1. Unique FDA-provided number for FDA-approved drugs
   24. Drug
       1. Drug provided to a specific arm of clinical trial
   25. Drug\_Class
       1. Subgroup of drug
   26. Control
       1. Identifies whether the control arm for the trial was an experimental arm
   27. Placebo\_ctrl
       1. Identifies whether the control arm for the trial was a placebo arm
   28. Filter
       1. Identifies whether average baseline SUA of trial arm is hyperuricemic, SUA > 6.8, or normouricemic
   29. Dose
       1. Dose prescribed to patients in a specific clinical trial arm
   30. Drug\_Delivery\_Route
       1. The method in which the drug is delivered to the patient
   31. Dose\_Frequency
       1. How many times drug is administered to patients
          1. Once - Drug is taken only on Day 1 of study
          2. Q8h - drug is administered every 8 hours
          3. Every 4 days - drug is administered every 4 days
          4. Daily - drug is administered 1 time per day
          5. Twice daily - drug is administered 2 times per day
          6. Weekly - drug is administered 1 time per week
          7. Biweekly - drug is administered 1 time per every 2 weeks
          8. Triweekly - drug is administered 1 time per every 3 weeks
          9. Monthly - drug is administered 1 time per every 4 weeks
          10. Single on day 1; as needed on days 2-5 - self-explanatory, unique to one clinical trial"
   32. Daily\_Dose\_mg
       1. Dose of drug provided to patients provided in milligrams
   33. Number\_Arm
       1. Number of patients in clinical trial arm
   34. Number\_Male
       1. Number of patients who identify as male in the clinical trial arm
   35. Number\_Female
       1. Number of patients who identify as female in the clinical trial arm
   36. Region
       1. Area where the trial was conducted
   37. Baseline\_GFR
       1. Initial Glomerular Filtration Rate (GFR) in mL/min
   38. Baseline\_GFR\_SD
       1. Standard Deviation of baseline GFR in mL/min
   39. Renal\_Impairment\_(Y/N)
       1. Indicator of Renal Impairment Status
   40. Renal\_Impairment\_#
       1. Indicator of Renal Impairment Status
   41. Renal\_Impairment\_Comments
       1. Trial's definition of renal impairment and % of subjects classified as renally impaired
   42. CKD
       1. Notes whether CKD patients were included
   43. No\_Data
       1. Notes whether CKD data was present
   44. Initial\_sUA\_mg/dL
       1. Notes whether CKD data was present
   45. SD(Initial\_sUA\_mg/dL)
       1. Standard Deviation of Initial serum Urate Level in mg/dL
   46. SE(Initial\_sUA\_mg/dL)
       1. Standard Deviation of Initial serum Urate Level in mg/dL
   47. LL\_95%\_CI((Initial\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Initial serum Urate Level in mg/dL
   48. UL\_95%\_CI((Initial\_sUA\_mg/dL)
       1. Upper Limit 95% Confidence Interval for Initial serum Urate Level in mg/dL
   49. Initial\_sUA\_SI
       1. Initial serum Urate level in μM/L
   50. SD(Initial\_sUA\_SI)
       1. Standard Deviation of Initial serum Urate level in μM/L
   51. SE(Initial\_sUA\_SI)
       1. Standard Error of Initial serum Urate level in μM/L
   52. LL\_95%\_CI(Initial\_sUA\_SI)
       1. Lower Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   53. UL\_95%\_CI(Initial\_sUA\_SI)
       1. Upper Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   54. Final\_sUA\_mg/dL
       1. Upper Limit 95% Confidence Interval for Initial serum Urate level in μM/L
   55. SD(Final\_sUA\_mg/dL)
       1. Standard Deviation of Final serum Urate level in μM/L
   56. SE(Final\_sUA\_mg/dL)
       1. Standard Error of Final serum Urate level in μM/L
   57. LL\_95%\_CI(Final\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Final serum Urate level in μM/L
   58. UL\_95%\_CI(Final\_sUA\_mg/dL)
       1. Lower Limit 95% Confidence Interval for Final serum Urate level in μM/L
   59. Final\_sUA\_SI
       1. Final serum Urate level in μM/L
   60. SD(Final\_sUA\_SI)
       1. Final serum Urate level in μM/L
   61. SE(Final\_sUA\_SI)
       1. Standard Error of Final serum Urate level in μM/L
   62. LL\_95%\_CI(Final\_sUA\_SI)
       1. Standard Error of Final serum Urate level in μM/L
   63. UL\_95%\_CI(Final\_sUA\_SI)
       1. Upper Limit 95% Confidence Interval for Final serum Urate level in μM/L
   64. Numeric Change in Uric Acid (mg/dL)
       1. Baseline SUA less final SUA
   65. Change
       1. Percentage of Urate Lowering converted to decimal format
   66. change.sd
       1. Standard Deviation of Percentage of Urate Lowering converted to decimal format
   67. change.se
       1. Standard Error of Percentage of Urate Lowering converted to decimal format
   68. Per
       1. Standard Error of Percentage of Urate Lowering converted to decimal format
   69. per.sd
       1. Standard Deviation of Percentage of Urate Lowering
   70. per.se
       1. Standard Deviation of Percentage of Urate Lowering
   71. LL\_95%\_CI(%\_UA\_Lowering)
       1. Lower Limit 95% Confidence Interval for Percentage of Urate Lowering
   72. UL\_95%\_CI(%\_UA\_Lowering)
       1. Lower Limit 95% Confidence Interval for Percentage of Urate Lowering
   73. Achieved\_Outcome\_%
       1. Percentage of patients achieving a specific outcome
   74. Number\_Achieved\_Outcome
       1. Number of patients achieving specific outcome
   75. Number\_NOT\_Achieved\_Outcome
       1. Number of patients failing to achieve a specific outcome
   76. SD(Achieved\_Outcome\_%)
       1. Standard Deviation of percentage of patients achieving a specific outcome
   77. SE(Achieved\_Outcome\_%)
       1. Standard Error of percentage of patients achieving a specific outcome
   78. LL\_95%\_CI(Achieved\_Outcome\_%)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   79. UL\_95%\_CI(Achieved\_Outcome\_%)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   80. Achieved\_Outcome\_P(x)
       1. Lower Limit 95% Confidence Interval for percentage of patients achieving a specific outcome
   81. LL\_95%\_CI(Achieved\_Outcome\_P(x))
       1. Lower Limit 95% Confidence Interval of the probability of achieving a specific outcome
   82. UL\_95%\_CI(Achieved\_Outcome\_P(x))
       1. Upper Limit 95% Confidence Interval of the probability of achieving a specific outcome
   83. ctrl.n
       1. Number of patients in the control trial arm for Achievement Difference analysis
   84. ctrl.ac
       1. Number of patients in the control trial arm for Achievement Difference analysis
   85. ctrl.nac
       1. Number of patients in control arm failing to achieve a specific outcome
   86. RR
       1. Relative Risk relating to the Control Arm
   87. SE(RR)
       1. Relative Risk relating to the Control Arm
   88. Days\_on\_Tx
       1. Number of days patients were on treatment
   89. Comments
       1. Number of days patients were on treatment
   90. Comments\_2
       1. Number of days patients were on treatment
   91. Uric Acid SI Unit Conversion Factor
       1. Number of days patients were on treatment